Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4257036 | 1.00 | NFKB1 (0.39) | NFKB1NFKB2RELACCR2HDAC4 | |
| SCHEMBL4257545 | 0.88 | CCR2 (0.38) | NFKB1NFKB2RELACCR2HDAC4 | |
| SCHEMBL4257550 | 0.88 | CCR2 (0.38) | NFKB1NFKB2RELACCR2HDAC4 | |
| SCHEMBL4259289 | 0.77 | NFKB1 (0.41) | NFKB1NFKB2RELACCR2HDAC4 | |
| SCHEMBL4259293 | 0.77 | NFKB1 (0.41) | NFKB1NFKB2RELACCR2HDAC4 | |
| SCHEMBL28380084 | 0.75 | NFKB1 (0.38) | NFKB1NFKB2RELACCR2BTK | |
| SCHEMBL28376416 | 0.74 | CTSK (0.40) | NFKB1NFKB2RELACCR2HDAC4 | |
| SCHEMBL421148 | 0.73 | CHRNA7 (0.53) | BTKGAA | |
| SCHEMBL421147 | 0.73 | CHRNA7 (0.53) | BTKGAA | |
| SCHEMBL10153346 | 0.73 | CHRNA7 (0.53) | BTKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833782-B1 | CYCLOALKYLAMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | EP | disclosed |
| US-7411093-B2 | Aminocycloalkanes as DPP-IV inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135512-A1 | Aminocycloalkanes as DPP-IV inhibitors | DPP4, DPP7, DPP3 | NFKB1 2483/4885NFKB2 3023/4885RELA 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.